Latest Information Update: 25 Mar 2017
At a glance
- Originator Alcon
- Class Antiglaucomas
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 14 May 2014 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
- 31 Mar 2007 Phase-II clinical trials in Glaucoma in USA (Ophthalmic)